Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale-New Haven Hospital, discusses the prevalence of immunotherapy-related adverse events.
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale-New Haven Hospital, discusses the prevalence of immunotherapy-related adverse events.
Burke says that approximately one-third of patients will develop a clinically-significant adverse drug reaction. Occasionally, these can develop into moderate or severe side effects. The three side effects that concern Burke most are dermatitis, enterocolitis, and endocrinopathy.
The prevalence of immunotherapy-related side effects is consistent across all studies, versions, and combinations of drugs, Burke says.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.